Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Preferred Shares (2024 - 2025)

Spyre Therapeutics' Preferred Shares history spans 3 years, with the latest figure at $146.4 million for Q4 2025.

  • For Q4 2025, Preferred Shares changed N/A year-over-year to $146.4 million; the TTM value through Dec 2025 reached $146.4 million, changed N/A, while the annual FY2025 figure was $146.4 million, N/A changed from the prior year.
  • Preferred Shares reached $146.4 million in Q4 2025 per SYRE's latest filing, up from $9.4 million in the prior quarter.
  • In the past five years, Preferred Shares ranged from a high of $146.4 million in Q3 2024 to a low of $9.4 million in Q2 2024.